Search This Blog

Tuesday, June 7, 2016

New Phase 3 Secondary Analysis Shows Progression-Free Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis® (Carfilzomib)-Based Regimen

Analysis Assessed Efficacy and Safety of Kyprolis in Combination With Lenalidomide and Dexamethasone (KRd) Using Results From Pivotal ASPIRE Trial



Amgen - Investors - RSS Content

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.